Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
February 15, 2024 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
February 06, 2024 04:00 ET
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
December 05, 2023 04:00 ET
|
AKAMPION
- Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001 Munich, Germany – December 05, 2023 – Thermosome, a drug development company specializing...
Thermosome Establishes High-Profile Clinical Advisory Board
September 19, 2023 04:00 ET
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
September 11, 2023 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Cancer Monoclonal Antibodies Market Is A $108.47 Billion Opportunity; Successful Cancer Therapeutic Strategies
November 10, 2022 07:02 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Worldwide Cancer Monoclonal Antibodies Market size in 2021 was USD 51.88 billion and will be worth USD 108.47 billion with an 8.54% CAGR. A...